Sildenafil does not have one universal storage instruction that can be applied to every product. Current U.S. labeling shows meaningful formulation-specific differences, particularly between tablets, powder for oral suspension, reconstituted suspension, ready-to-use liquid products, oral film and intravenous injection.
Many current sildenafil tablets, REVATIO tablets, REVATIO injection, LIQREV oral suspension and sildenafil oral film use controlled-room-temperature conditions around 20°C to 25°C with permitted excursions to 15°C to 30°C. However, exact wording can differ by product: current VIAGRA labeling, for example, specifies storage at 25°C with excursions to 15°C to 30°C.
The largest differences occur with oral suspensions. REVATIO powder must be protected from moisture before reconstitution and can be refrigerated after reconstitution, while LIQREV is supplied ready to use and follows a room-temperature storage framework with its own 90-day after-opening handling period.
Storage instructions define the environmental and packaging conditions under which a specific sildenafil product is expected to remain within its validated quality specifications.
Those instructions can address temperature, permitted excursions, moisture protection, container type, refrigeration, freezing restrictions and in-use handling after a product is opened or reconstituted.
The active ingredient name alone is therefore not enough to determine storage. The exact branded or generic product, dosage form and current label must be identified first.
| Storage Element | What It Can Define |
|---|---|
| Temperature | Routine labeled storage range |
| Temperature excursion | Permitted temporary deviation from the routine range |
| Container / pouch | Product-specific physical protection |
| Moisture protection | Required for selected formulations such as powder before reconstitution |
| Refrigeration | Permitted or required only when the specific label states it |
| Freezing | Can be specifically prohibited for liquid formulations |
| In-use period | Time allowed after opening or reconstitution before unused product is discarded |
Approved storage conditions are supported by pharmaceutical stability data. They define the conditions under which the manufacturer has established product quality for the labeled shelf-life or in-use period.
Storage outside the labeled conditions does not automatically establish that a product has become unusable, but the label no longer provides the same validated assurance for that exposure. Decisions after substantial temperature or handling deviations depend on the exact product and circumstances rather than a universal sildenafil rule.
Storage and expiration are connected but different concepts. Storage describes the conditions required to support stability, while expiration and in-use discard dates define validated time limits.
| Factor | Why It Matters |
|---|---|
| Labeled temperature | Supports validated chemical and physical stability |
| Moisture protection | Can protect moisture-sensitive product presentations |
| Container integrity | Preserves the labeled packaging environment |
| No-freeze instruction | Prevents exposure outside validated liquid-product conditions |
| Reconstitution / opening date | Can start a separate in-use stability period |
| Expiration date | Defines the manufacturer's unopened shelf-life limit under labeled storage |
A common current U.S. storage pattern for sildenafil products is controlled room temperature at 20°C to 25°C, or 68°F to 77°F, with excursions permitted from 15°C to 30°C, or 59°F to 86°F.
That pattern appears in current REVATIO tablets and injection, many generic sildenafil tablet labels, LIQREV oral suspension and sildenafil oral film labeling.
It should not be converted into a universal statement that every sildenafil product is labeled identically. Current VIAGRA labeling specifies storage at 25°C with excursions permitted between 15°C and 30°C, while REVATIO powder before reconstitution instead specifies storage below 30°C with moisture protection.
The exact label therefore takes priority over a generalized room-temperature summary.
| Product Example | Current Labeled Storage |
|---|---|
| REVATIO tablet | 20–25°C (68–77°F); excursions 15–30°C (59–86°F) |
| REVATIO injection | 20–25°C (68–77°F); excursions 15–30°C (59–86°F) |
| Many current generic sildenafil tablets | 20–25°C (68–77°F); many labels permit excursions 15–30°C (59–86°F) |
| VIAGRA tablet | 25°C (77°F); excursions 15–30°C (59–86°F) |
| LIQREV | 20–25°C (68–77°F); excursions 15–30°C (59–86°F) |
| VYBRIQUE / sildenafil oral film | 20–25°C (68–77°F); excursions 15–30°C (59–86°F) |
| REVATIO powder before reconstitution | Below 30°C (86°F) in original package; protect from moisture |
Current tablet labels generally place sildenafil within USP controlled-room-temperature conditions, but exact wording and packaging instructions can differ between branded and generic products.
Current REVATIO tablets are stored at 20°C to 25°C with excursions to 15°C to 30°C and are labeled to be dispensed in tight containers. Many current generic 20 mg sildenafil tablet labels use the same temperature framework.
Current VIAGRA labeling instead states 25°C with excursions to 15°C to 30°C. Other generic ED sildenafil labels can state 20°C to 25°C, showing why the exact dispensed product label remains the appropriate source.
A tablet should therefore not be assigned a storage requirement solely from its strength or from the fact that it contains sildenafil.
| Tablet Product Context | Temperature Example | Packaging / Label Note |
|---|---|---|
| REVATIO 20 mg tablet | 20–25°C; excursions 15–30°C | Dispense in tight containers |
| Generic PAH-context sildenafil 20 mg | Commonly 20–25°C; excursions often 15–30°C | Exact manufacturer label applies |
| VIAGRA 25/50/100 mg | 25°C; excursions 15–30°C | VIAGRA-specific labeling |
| Generic ED sildenafil tablets | Current labels commonly use controlled-room-temperature conditions | Exact manufacturer and package instructions can differ |
| Detailed tablet information | Sildenafil Tablets | Dedicated dosage-form resource |
Sildenafil oral suspension requires product-specific identification because current U.S. products include both powder that must be reconstituted and a separate ready-to-use suspension.
REVATIO powder for oral suspension is stored below 30°C in the original package before reconstitution in order to protect it from moisture. After labeled reconstitution, the 10 mg/mL suspension can be stored below 30°C or refrigerated at 2°C to 8°C, must not be frozen and any unused portion is discarded 60 days after reconstitution.
LIQREV is different: it is supplied as a ready-to-use 10 mg/mL suspension. Its label specifies 20°C to 25°C with excursions to 15°C to 30°C and instructs that unused product be discarded 90 days after first opening.
These instructions should not be transferred from one suspension to another. The sildenafil oral suspension page covers the formulation differences in detail.
| Suspension Product / Stage | Current Storage / Handling |
|---|---|
| REVATIO powder — before reconstitution | Store below 30°C (86°F) in original package; protect from moisture |
| REVATIO suspension — after reconstitution | Store below 30°C (86°F) or refrigerate at 2–8°C (36–46°F) |
| REVATIO suspension — freezing | Do not freeze |
| REVATIO suspension — in-use period | Discard unused portion 60 days after reconstitution |
| LIQREV ready-to-use suspension | 20–25°C (68–77°F); excursions 15–30°C (59–86°F) |
| LIQREV after first opening | Discard unused portion 90 days after first opening |
| Detailed formulation guide | Sildenafil Oral Suspension |
REVATIO injection is a sterile, ready-to-use intravenous sildenafil formulation supplied in a single-dose vial. Its current label specifies controlled room-temperature storage at 20°C to 25°C with excursions permitted to 15°C to 30°C.
The single-dose designation also affects handling after the vial is used: current product labeling instructs that unused portion be discarded.
No refrigerator requirement should be inferred from the storage instructions for reconstituted oral suspension. The injectable and oral-liquid products have separate validated storage conditions.
Detailed product and route information remains on the sildenafil injection page.
| Injection Feature | Current REVATIO Context |
|---|---|
| Dosage form | Sterile ready-to-use intravenous solution |
| Container | Single-dose vial |
| Routine storage | 20–25°C (68–77°F) |
| Permitted excursions | 15–30°C (59–86°F) |
| Unused portion | Discard after single-dose use |
| Detailed resource | Sildenafil Injection |
Packaging can be part of the labeled storage system rather than merely a method of dispensing the product. Instructions therefore differ by formulation.
REVATIO powder is specifically labeled for storage in its original package before reconstitution to protect it from moisture. REVATIO tablets are labeled for dispensing in tight containers.
Current sildenafil oral film products such as VYBRIQUE are supplied as individually sealed foil pouches. The sealed unit presentation is part of that product's packaging configuration.
Because generic tablet manufacturers and other sildenafil products can use different bottles, blisters or unit-dose systems, one product's container instruction should not automatically be applied to another.
| Product / Formulation | Packaging Context |
|---|---|
| REVATIO tablet | Dispense in tight containers |
| REVATIO powder for oral suspension | Keep in original package before reconstitution to protect from moisture |
| VYBRIQUE / sildenafil oral film | Each oral film supplied in an individually sealed foil pouch |
| REVATIO injection | Sterile single-dose glass vial |
| Generic sildenafil tablets | Bottle, blister or unit-dose packaging depends on manufacturer |
Temperature is the most consistently specified storage variable across current sildenafil labels, but selected products also carry moisture, container or freezing instructions.
REVATIO powder provides the clearest sildenafil-specific moisture example: the unreconstituted powder is stored in the original package specifically to protect it from moisture.
The reconstituted REVATIO suspension provides a separate physical-condition restriction because the label states that it must not be frozen.
Light-protection requirements should not be generalized to sildenafil as a drug class. Some manufacturer-specific tablet labels specify light-resistant containers, while others use different packaging language. The exact product label should therefore be followed.
| Environmental Factor | Sildenafil Example |
|---|---|
| Temperature | Specified across tablet, suspension, film and injection labels |
| Moisture | REVATIO powder before reconstitution must be protected from moisture |
| Freezing | Reconstituted REVATIO oral suspension must not be frozen |
| Refrigeration | Permitted for reconstituted REVATIO suspension at 2–8°C |
| Light protection | Can be manufacturer- or package-specific rather than universal to sildenafil |
| Sealed packaging | Oral film is supplied in individual foil pouches |
Current U.S. VIAGRA labeling specifies storage at 25°C, or 77°F, with excursions permitted between 15°C and 30°C, or 59°F and 86°F.
That wording is slightly different from the 20°C to 25°C controlled-room-temperature range used by many current generic sildenafil products and REVATIO. The difference demonstrates why a broad statement such as 'all sildenafil is stored at 20–25°C' would be too absolute.
VIAGRA storage applies to the branded tablet product and should not be automatically transferred to suspensions, injection, oral film or every generic tablet presentation.
| VIAGRA Storage Element | Current Label |
|---|---|
| Dosage form | Film-coated tablet |
| Recommended temperature | 25°C (77°F) |
| Permitted excursions | 15–30°C (59–86°F) |
| Scope | VIAGRA-specific product labeling |
| Brand relationship | Sildenafil and Viagra |
REVATIO is a useful example of why storage must be matched to formulation even within a single sildenafil brand family.
Current REVATIO tablets and injection use controlled room temperature at 20°C to 25°C with excursions to 15°C to 30°C. Unreconstituted powder for oral suspension instead uses a below-30°C limit with original-package moisture protection.
After the powder is reconstituted, the suspension can remain below 30°C or be refrigerated at 2°C to 8°C, cannot be frozen and has a 60-day in-use period.
These are formulation-specific rules inside one brand, not evidence that every sildenafil product has the same storage profile. Product identity is covered further on the sildenafil and Revatio page.
| REVATIO Form | Current Storage Context |
|---|---|
| 20 mg tablet | 20–25°C; excursions 15–30°C |
| Powder before reconstitution | Below 30°C in original package; protect from moisture |
| Reconstituted 10 mg/mL suspension | Below 30°C or 2–8°C refrigerated; do not freeze |
| Reconstituted suspension in-use period | Discard after 60 days |
| Injection | 20–25°C; excursions 15–30°C |
| Brand / product guide | Sildenafil and Revatio |
Storage and expiration are related but separate stability concepts. Storage defines environmental and handling conditions; expiration defines how long an unopened product remains within its validated shelf life when those conditions are met.
Some formulations also acquire a separate in-use time limit after preparation or opening. REVATIO suspension is discarded 60 days after reconstitution, while LIQREV is discarded 90 days after first opening.
Those in-use limits do not replace the printed manufacturer expiration date in every circumstance and should not be generalized from one sildenafil product to another.
The broader interpretation of labeled expiration dates, in-use periods and expired sildenafil belongs on the sildenafil expiration page.
| Concept | Meaning |
|---|---|
| Storage condition | Environmental requirements used to support stability |
| Printed expiration date | Manufacturer's labeled shelf-life limit for the product |
| Reconstitution date | Starts the REVATIO reconstituted-suspension in-use period |
| First-opening date | Starts the LIQREV 90-day in-use period |
| In-use discard period | Product-specific time limit after opening or preparation |
| Detailed expiration guide | Sildenafil Expiration |
The physical form and packaging of a medicine determine which stability questions must be addressed. A dry tablet, moisture-sensitive powder, aqueous suspension, sterile injection and thin oral film do not present the same storage challenges.
Current sildenafil products demonstrate that difference directly. Tablets and injection generally use controlled-room-temperature storage; REVATIO powder adds moisture protection; reconstituted REVATIO suspension permits refrigeration and prohibits freezing; LIQREV has a first-opening in-use period; and oral film is individually sealed in foil pouches.
Formulation-specific storage information therefore provides more useful guidance than a single generic statement about sildenafil.
| Formulation | Distinctive Storage / Handling Feature |
|---|---|
| Tablet | Controlled-room-temperature storage; exact product wording and container requirements vary |
| Powder for oral suspension | Protect from moisture before reconstitution |
| Reconstituted REVATIO suspension | Room-temperature or refrigerated storage; do not freeze; 60-day in-use period |
| LIQREV ready-to-use suspension | Controlled room temperature; 90-day period after first opening |
| Injection | Controlled room temperature; sterile single-dose vial |
| Oral film | Controlled room temperature; individually sealed foil pouch |
| Formulation map | Sildenafil Formulations |
It depends on the exact product. Many current U.S. sildenafil tablets, REVATIO tablets and injection, LIQREV and sildenafil oral film use 20°C to 25°C with excursions to 15°C to 30°C. Current VIAGRA labeling specifies 25°C with excursions to 15°C to 30°C, while REVATIO powder before reconstitution is stored below 30°C with moisture protection.
The answer depends on the product. Reconstituted REVATIO suspension may be stored below 30°C or refrigerated at 2°C to 8°C and must not be frozen. LIQREV is a different ready-to-use suspension labeled for controlled room temperature rather than the REVATIO reconstitution-storage framework.
Current REVATIO labeling states that unused reconstituted suspension should be discarded 60 days after reconstitution. That is a product-specific in-use period.
Current LIQREV labeling states that unused suspension should be discarded 90 days after first opening.
Current REVATIO labeling specifically states that the reconstituted oral suspension should not be frozen. Storage instructions for other sildenafil liquid products should be checked separately.
No. Current U.S. tablet labels commonly use USP controlled-room-temperature conditions, but the exact wording and container requirements can differ by branded or generic product and manufacturer.
No. Storage defines the environmental and handling conditions for the product, while expiration defines its validated shelf-life limit. Some liquid products also have separate discard periods after reconstitution or first opening.